Eikonizo Therapeutics
Eikonizo Therapeutics is a biopharmaceutical company developing disease-modifying therapies for neurodegenerative and cardiorenal diseases. Their lead candidate, EKZ-102, is a first-in-class, oral HDAC6 inhibitor designed to protect neuronal function while minimizing side effects. The company aims to provide novel treatments targeting key drivers of these diseases.
Funding Round: Equity
Funding Amount:
Date: 10-Dec-2024
Investors: Novo Nordisk
Markets: Biopharmaceuticals, Neurodegenerative Diseases, Cardiorenal Diseases
HQ: Cambridge, Massachusetts, United States
Founded: 2017
Website: https://eikonizo.com/
LinkedIn: https://www.linkedin.com/company/eikonizo-therapeutics
Twitter: https://twitter.com/Eikonizo
Crunchbase: https://www.crunchbase.com/organization/eikonizo-therapeutics
Leave a Comment
Comments
No comments yet.